CSF2 and prostate carcinoma: This vaccine works by boosting the patient’s immune system, using the patient’s own immune cells, which are modified with a recombinant fusion protein comprising prostatic acid phosphatase (PAP)—a common prostate cancer antigen—and granulocyte-macrophage colony-stimulating factor (GM-CSF) [77].